Infections associated with tumor necrosis factor-α antagonists

Medicine

Volumn 84, Issue 5, 2005, Pages 291-302

  Crum, Nancy F ^a   Lederman, Edith R ^b   Wallace, Mark R ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b US Naval Medical Research Unit No 2 Jakarta   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMOXICILLIN; AMPHOTERICIN B LIPID COMPLEX; COTRIMOXAZOLE; ETANERCEPT; ETHAMBUTOL; FLUCONAZOLE; FLUOROURACIL; INFLIXIMAB; ISONIAZID; ITRACONAZOLE; PENICILLIN G; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ASPERGILLOSIS; ATYPICAL MYCOBACTERIOSIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CANDIDIASIS; CASE REPORT; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; FEMALE; HISTOPLASMOSIS; HUMAN; INFECTION; INFECTION RISK; LEGIONNAIRE DISEASE; LISTERIOSIS; MALE; MILIARY TUBERCULOSIS; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SCREENING; STREPTOCOCCUS PNEUMONIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BACTERIAL INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYCOSES; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 25444497016     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.md.0000180044.19285.9a     Document Type: Review

References (121)

1. Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol. 1998;160:6072-6082.
2. Altz-Smith M, Kendall LG Jr, Stamm AM. Cryptococcus associated with low-dose methotrexate for arthritis. Am J Med. 1987;83:179-181.
3. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52:1-77.
4. Anonymous. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47(RR-20):1-58.
5. Anonymous. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49(6):1-51.
6. Aparicio AG, Munoz-Fernandez S, Bonilla G, Miralles A, Cerdeno V, Martin-Mola E. Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment. Arthritis Rheum. 2003;48:1764-1765.
7. Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, Minoprio P. Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and dependent phases of Mycobacterium avium infection. Infect Immun. 1994;62:3962-3971.
8. Arend SM, Breedveld FC, van Dissel JT. TNFα blockade and tuberculosis: better look before you leap. J Med. 2003;61:111-119.
9. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001;76:653-656.
10. Bala S, Hastings KL, Kazempour K, Inglis S, Dempsey WL. Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex in mice. Antimicrob Agents Chemother. 1998;42:2336-2341.
11. Bauman SK, Huffnagle GB, Murphy JW. Effects of tumor necrosis factor alpha on dendritic cell accumulation in lymph nodes draining the immunization site and the impact on the anticryptococcal cell-mediated immune response. Infect Immun. 2003;71:68-74.
12. Baumgart DC, Diagnass AU. Shingles following infliximab infusion. Ann Rheum Dis. 2002;61:661.
13. Beaman L. Effects of recombinant gamma interferon and tumor necrosis factor on in vitro interactions of human mononuclear phagocytes with Coccidiodes immitis. Infect Immun. 1991;59:4227-4229.
14. Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, Britton WJ. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 1999;162:3504-3511.
15. Beretich GR Jr, Carter PB, Havell EA. Roles for tumor necrosis factor and gamma interferon in resistance to enteric listeriosis. Infect Immun. 1998;66:2368-2373.
16. Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 2004;50:1959-1966.
17. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int. 2004;25:331-335.
18. Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl Infect Dis. 2003;5:3-8.
19. Bowie VL, Snella KA, Gopalachar ankylosing spondylitis, Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother. 2004;38:58-61.
20. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002;359:1187-1193.
21. Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. Morb Mortal Wkly Rep. 2004;53:683-686.
22. Centers for Disease Control and Prevention. Listeriosis. Available at http://www.cdc.gov/ncidod/dbmd/diseaseinfo/listeriosis_g.htm. Accessed 12/3/04.
23. Chan AT, Cleeve V, Daymond TJ. Necrotizing fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J. 2002;78:47-48.
24. Coaccioli S, Di Cato L, Marioli D, Patucchi E, Pizzuti C, Ponteggia M, Puxeddu A. Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Medica. 2000;42:253-256.
25. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience of 500 patients. Gastroenterology. 2004;126:19-31.
26. Corry DB, Ampel NM, Christian L, Locksley RM, Galgiani JN. Cytokine production by peripheral blood mononuclear cells in human coccidioidomycosis. J Infect Dis. 1996;174:440-443.
27. Coyle CM, Weiss LM, Rhodes LV 3rd, Cali A, Takvorian PM, Brown DF, Visvesvara GS, Xiao L, Naktin J, Young E, Gareca M, Colasante G, Winner M. Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N Engl J Med. 2004;351:42-47.
28. Crum NF, Lederman ER, Stafford CM, Parrish JS, Wallace MR. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore). 2004;83:149-175.
29. Cursiefen C, Grunke M, Dechant C, Antoni C, Junemann A, Holback LM. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNF-alpha-antibody and methotrexate therapy. Am J Ophthalmol. 2002;134:270-271.
30. De Rosa FG, Bonora S, Di Perri G. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:623-626.
31. Derk CT, DeHoratius RJ. Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis. 2003;62:372.
32. Dewsnup DH, Galgiani JN, Graybill JR, Diaz M, Rendon A, Cloud GA, Stevens DA. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis. Ann Intern Med. 1996;124:305-310.
33. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. [WHO Global Surveillance and Monitoring Project.] Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. JAMA. 1999;282:677-686.
34. Ehlers S, Benini J, Kutsch S, Endres R, Rietschel ET, Pfeffer K. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect Immun. 1999;67:3571-3579.
35. Fenhalls G, Wong A, Bezuidenhout J, van Helden P, Bardin P, Lukey PT. In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun. 2000;68:2827-2836.
36. Fischkoff S. Preliminary analysis of phase I and II safety data from the Adalimumab (D2E7) Clinical Trials Program. In: Abstracts of the Advances in Targeted Therapies Meeting, Nassau, Bahamas, April 27-May 1, 2001.
37. Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther. 2004;6 (Suppl 2): S12-18.
38. Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis. 2002;61(Suppl):62-63.
39. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh, DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and management. Lancet Infect Dis. 2003;3:148-155.
40. Deleted.
41. Gluck T, Linde HJ, Scholmerich J, Muller-Ladner U, Fiehn C, Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 2002;46:2255-2257.
42. Hage CA, Wood KL, Winer-Muram HT, Wilson SJ, Sarosi G, Knox KS. Pulmonary crytpococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest. 2003;124:2395-2397.
43. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol. 2004;16:393-398.
44. Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA, Powderly W. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:100-107.
45. Helbling D, Breitback TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumor necrosis factor therapy. Eur J Gastroenterol Hepatol. 2002;14:1393-1395.
46. Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor α for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect Immun. 2002;70:2959-2964.
47. Huffnagle GB, Toews GB, Burdick MD, Boyd MD, McAllister KS, McDonald RA, Kunkel SL, Stricter RM. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol. 1996;157:4529-4536.
48. Jacobs M, Brown N, Allie N, Chetty K, Ryffel B. Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity. Pathobiology. 2000;68:68-75.
49. Joosten AA, van Olffen GH, Hageman G. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy.] Ned Tijdschr Geneeskd. 2003;147:1470-1472.
50. Kamath BM, Mamula P, Baldassano RN, Markowitz JE. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr. 2002;34:410-412.
51. Kaplan G, Freedman VH. The role of cytokines in the immune response to tuberculosis. Res Immunol. 1996;147:565-572.
52. Kaplan JE, Masur H, Holmes KK. USPHS. Infectious Disease Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. MMWR Recomm Rep. 2002;51 (RR-8):1-52.
53. Kato K, Nakane A, Minagawa T, Kasai N, Yamamoto K, Sato N, Tsuruoka N. Human tumor necrosis factor increases the resistance against listeria infection in mice. Med Microbiol Immunol. 1989;178:337-346.
54. Kavanaugh A, Keenan S, De Woody K, Marsters P, Hendricks D, Clark J, Harriman G. Long term follow up of patients with Remicade (infliximab) in clinical trials (abstract #173). Arthritis Rheum. 2001;44S:S81.
55. Keane J. Tumor necrosis factor blockers and reactivation of latent tuberculosis. Clin Infect Dis. 2004;39:300-302.
56. Keane J, Gershon S, Braun MM. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:625-626.
57. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
58. Keenan GF, Schaible TF, Boscia JA. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344:1100.
59. Klinkhoff A. Biological agents for rheumatoid arthritis. Drugs. 2004;64:1267-1283.
60. Kolls JK, Lei D, Vasquez C, Odom G, Summer WR, Nelson S, Shellito J. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J Respir Cell Mol BM. 1997;16:112-118.
61. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology (Oxford). 2003;42:617-621.
62. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570.
63. Levitz SM. The ecology of Cryptoccous neoformans and the epidemiology of cryptococcosis. Rev Infect Dis. 1991;13:1163-1169.
64. Levitz SM. Overview of host defenses in fungal infections. Clin Infect Dis. 1992;14:S37-42.
65. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ. 2003;168:1153-1156.
66. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157.
67. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necroiss factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-1939.
68. Manadan AM, Mohan AK, Cote TR, Siegal JN, Sequeria W, Block JA. Tuberculosis and etanercept. (Abstract #356). American College of Rheumatology Conference, New Orleans, LA, October 24-29, 2002.
69. Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, Hiele M, Bueno De Mesquita M, D'Hoore A, Penninckx F, Rutgeerts P. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004;19:749-754.
70. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis. 2003;62:791.
71. Mathew G, Smedema M, Wheat LJ, Goldman M. Relapse of coccidioidomycosis despite immune reconstitution after fluconazole secondary prophylaxis in a patient with AIDS. Mycoses. 2003;46:42-44.
72. Mayordomo L, Marenco JL, Gomez-Mateos J, Rejon E. Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol. 2002;31:44-45.
73. McKinsey DS, Spiegal RA, Hutwagner L. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis. 1997;24:1195-1203.
74. McKinsey DS, Wheat LF, Cloud GA, Pierce M, Black JR, Bamberger DM, Goldman M, Thomas CJ, Gutsch HM, Moskovitz B, Dismukes WE, Kauffman CA. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999;28:1049-1056.
75. Mehrad B, Strieter RM, Standiford TJ. Role of TNF alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol. 1999;162:1633-1640.
76. Mohan AK, Cote TR, Siegel JN, Braun MM. Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol. 2003;15:179-184.
77. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39:295-299.
78. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, Tsai MM, Flynn, JL, Chan J. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun. 2001;69:1847-1855.
79. Mow WS, Abrau-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2:309-313.
80. Nakane A, Minagawa T, Kohanawa M, Chen Y, Sato H, Moriyama M, Tsurouka N. Interactions between endogenous gamma interferon and tumor necrosis factor in host resistance against primary and secondary Listeria monocytogenes infections. Infect Immun. 1989;57:3331-3337.
81. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab [letter]. Am J Med. 2002;112:78.
82. Newman SL. Cell-mediated immunity to Histoplasma capsulatum. Semin Respir Infect. 2001;16:102-108.
83. Nishikawa S, Miura T, Sasaki S, Nakane A. The protective role of endogenous cytokines in host resistance against an intragastric infection with Listeria monocytogenes in mice. FEMS Immunol Med Microbiol. 1996;16:291-298.
84. Olivieri I, Padula A, Armignacco L, Sabatella V, Mancino M. Septic arthritis caused by Moraxella catarrhalis associated with infliximab treatment in a patient with undifferentiated spondyloarthritis. Ann Rheum Dis. 2004;63:105-106.
85. Pagliano P, Attanasio V, Fusco U, Mohamed DA, Rossi M, Faella FS. Does etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis? Ann Rheum Dis. 2004;63:462-463.
86. Paimela L, Johansson-Stephansson EA, Koskimies S, Leirisalo-Repo M. Depressed cutaneous cell-mediated immunity in early rheumatoid arthritis. Clin Exp Rheumatol. 1990;8:433-437.
87. Parra Ruiz J, Ortego Centeno N, Raya Alvarez R. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol. 2003;30:1657-1658.
88. Peddi VR, Hariharan S, First MR. Disseminated histoplasmosis in renal allograft recipients. Clin Transplant. 1996;10:160-165.
89. Pfeffer K, Matsuyama T, Kunding TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kranke M, Mak TW. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73:457-467.
90. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center, are the infection rates increased? Arthritis Care Res. 2002;47:17-21.
91. Reichardt P, Dahnert I, Tiller G, Hausler HJ. Possible activation of an intramyocardial inflammatory process (Staphylococcus aureus) after treatment with infliximab in a boy with Crohn disease. Eur J Pediatr. 2002;161:281-283.
92. Roach DR, Bean AD, Demangel C, France MP, Briscoe H, Britton W. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002;168:4620-4627.
93. Salmon D. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine. 2002;69:170-172.
94. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251-259.
95. Shrestha RK, Stoller JK, Honari G, Procop GW, Gordon SM. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care. 2004;49:606-608.
96. Skerrett SJ, Bagby GJ, Schmidt RA, Nelson S. Antibody-mediated depletion of tumour necrosis factor-α impairs pulmonary host defenses to Legionella pneumonophilia. J Infect Dis. 1997;176:1019-1028.
97. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agent. Arthritis Rheum. 2003;48:319-324.
98. Slovis BS, Plitman JD, Haas DW. The case against anergy testing as a routine adjunct to tuberculin skin testing. JAMA. 2000;283:2003-2007.
99. Smith JG, Magee DM, Williams DM, Graybill JR. Tumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatum. J Infect Dis. 1990;162:1349-1353.
100. Smith S, Liggitt D, Jeromsky E, Tan X, Skerrett SJ, Wilson CB. Local role for tumor necrosis factor alpha in the pulmonary inflammatory response to Mycobacterium tuberculosis infection. Infect Immun. 2002;70:2082-2089.
101. Starrett WG, Czachor J, Dallal M, Drehmer T. Cryptococcal pneumonia following treatment with infliximab for rheumatoid arthritis. (Abstract #374.) 40th Annual Meeting of the Infectious Disease Society of America, Chicago, IL, October 24-27, 2002.
102. Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford). 2002;41:951-952.
103. True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthiritis treated with methotrexate and infliximab. J Rheumatol. 2002;29:1561-1563.
104. Tweezer-Zaks N, Shiloach E, Spivak A, Rapoport M, Novis B, Langevitz P. Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor-alpha. Isr Med Assoc J. 2003;5:829-830.
105. US Food and Drug Administration. Arthritis Drugs Advisory Committee: Safety update on TNF-a antagonists: infliximab and etanercept. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2.htm. Accessed 12/3/04.
106. Deleted.
107. US Food and Drug Administration, vol 2004: FDA, http://www.fda. gov/medwatch/SAFETY/2004/jun_PI/Humira_PI.pdf. Accessed 12/6/04.
108. Van den Brande JM, Braat GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785.
109. van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med. 2003;29:2327-2329.
110. Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis. 2003;62:1241-1242.
111. Wagner TE, Huseby ES, Huseby JS. Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with tumor necrosis factor-alpha inhibitor. Am J Med. 2002;112:67-69.
112. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-1265.
113. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344:1099-1100.
114. Wheat J. Histoplasmosis. Experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore). 1997;76:339-354.
115. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50:372-379.
116. Wondergem MJ, Voskuyl AE, van Agtmael MA. A case of legionellosis during treatment with a TNF-alpha antagonist. Scand J Infect Dis. 2004;36:310-320.
117. Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, Wheat LF, Twigg HL 3rd. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003;167:1279-1282.
118. Wu-Hsieh BA, Lee G-S, Franco M, Hofman FM. Early activation of splenic macrophages by tumor necrosis factor alpha is important in determining the outcome of experimental histoplasmosis in mice. Infect Immun. 1992;60:4230-4238.
119. Erratum in: Infect Immun. 1992;60:5324.
120. Zandman-Goddard G. Infection and anti-tumor necrosis factor-alpha therapy. Isr Med Assoc J. 2003;5:814-816.
121. Zhang Z, Correa H, Begue RE. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:623-626.